Table 2.
Number of women reporting local and systemic adverse reactions during the first 7 days after vaccination
| HIV-infected, low CD4 cell count (n=87) | HIV-infected, high CD4 cell count (n=88) | HIV-uninfected (n=90) | ||
|---|---|---|---|---|
| Local | ||||
| Any local | 16 (18%) | 26 (30%) | 35 (39%) | |
| Ecchymosis | 0 | 0 | 1 (1%) | |
| Erythema | 0 | 1 (1%) | 1 (1%); n=89 | |
| Induration | 0 | 1 (1%) | 0 | |
| Swelling | 0 | 0 | 2 (2%) | |
| Pain | ||||
| Any | 16 (18%) | 26 (30%) | 35 (39%) | |
| Severe | 2 (2%) | 0 | 4 (4%) | |
| Systemic | ||||
| Any systemic | 35 (40%) | 48 (55%) | 53 (59%) | |
| Chills | ||||
| Any | 8 (9%) | 12 (14%) | 20 (22%) | |
| Severe | 1 (1%) | 1 (1%) | 0 | |
| Nausea | ||||
| Any | 11 (13%) | 15 (17%) | 20 (22%); n=89 | |
| Severe | 1 (1%) | 0 | 2 (2%); n=89 | |
| Malaise | ||||
| Any | 9 (10%) | 17 (19%) | 21 (23%) | |
| Severe | 1 (1%) | 0 | 1 (1%) | |
| Myalgia | 7 (8%) | 15 (17%) | 21 (23%) | |
| Arthralgia | ||||
| Any | 11 (13%) | 20 (23%) | 26 (29%) | |
| Severe | 0 | 0 | 1 (1%) | |
| Headache | ||||
| Any | 21 (24%) | 28 (32%) | 39 (43%) | |
| Severe | 1 (1%) | 1 (1%) | 2 (2%) | |
| Fatigue | ||||
| Any | 21 (24%) | 27 (31%) | 42 (47%) | |
| Severe | 2 (2%) | 1 (1%) | 3 (3%) | |
| Rash | 3 (3%) | 1 (1%) | 1 (1%) | |
| Fever (≥38°C) | 3 (3%) | 0 | 0 | |
For local adverse reactions, no participants reported severe reactions (>100 mm), with the exception of pain. Data are given for local reactions (≥25 mm).